Rachlis A R, Zarowny D P
St. Paul's Hospital, Vancouver BC.
CMAJ. 1998 Feb 24;158(4):496-505.
To develop guidelines for health care providers and their HIV-positive patients on the clinical use of antiretroviral agents for HIV infection.
Recommendations published in 1996 by an international panel.
Improvement in clinical outcomes or in surrogate markers of disease activity. EVIDENCE AND VALUES: The Canadian HIV Trials Network held a workshop on Oct. 19-20, 1996, to develop Canadian guidelines that incorporate information from recent basic and clinical research.
Recommendations for the use of antiretroviral drugs in HIV infection are provided for initial therapy, continuing therapy, primary infection, vertical transmission, pediatric therapy and postexposure prophylaxis.
The guidelines are based on consensus of the participants attending the workshop: Canadian investigators, clinicians and invited representatives from the community, government and the pharmaceutical industry. They are subject to review and updating as new information on clinical benefits is published.
The workshop was organized by the National Centre of the Canadian HIV Trials Network. Unrestricted educational grants were provided by 8 pharmaceutical companies. Additional support was provided from the National AIDS Strategy of Health Canada.
为医疗保健提供者及其感染艾滋病毒的阳性患者制定关于抗逆转录病毒药物用于艾滋病毒感染临床治疗的指南。
1996年一个国际小组发表的建议。
改善临床结果或疾病活动的替代指标。证据和价值观：加拿大艾滋病毒试验网络于1996年10月19日至20日举办了一次研讨会，以制定纳入近期基础和临床研究信息的加拿大指南。
针对艾滋病毒感染中抗逆转录病毒药物的使用，提供了关于初始治疗、持续治疗、原发性感染、垂直传播、儿科治疗和暴露后预防的建议。
这些指南基于参加研讨会的人员达成的共识，包括加拿大研究人员、临床医生以及来自社区、政府和制药行业的特邀代表。随着关于临床益处的新信息发布，这些指南会接受审查和更新。
该研讨会由加拿大艾滋病毒试验网络国家中心组织。8家制药公司提供了无限制教育赠款。加拿大卫生部国家艾滋病战略提供了额外支持。
